Trials / Completed
CompletedNCT00496821
Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus
A Study to Investigate the Safety and Efficacy of Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (estimated)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the safety, tolerability and efficacy of intranasal ALN-RSV01 versus placebo, administered once daily for 5 days to a healthy male volunteers experimentally inoculated with RSV
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALN-RSV01 |
Timeline
- Start date
- 2007-07-01
- Completion
- 2007-11-01
- First posted
- 2007-07-04
- Last updated
- 2007-11-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00496821. Inclusion in this directory is not an endorsement.